

Errata

Menu E, Jernberg-Wiklund H, Stromberg T, et al. Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. *Blood*. 2006;107(2):655-660.

On page 658 in the 15 January 2006, issue, there is an error in Figure 3; panel 3A and 3C are reversed. The corrected figure is shown.




Figure 3. Effect of PPP in vivo. (A) Serum paraprotein concentrations as determined by serum electrophoresis. (B) Tumor load as determined by flow cytometric analysis. Data are expressed as percentage 5T33MM cells of total cell number. (C-D) Weight of spleen and liver in grams of naive and treated or untreated 5T33MM-bearing mice. (E) Microvessel density. The number of microvessels in the tibiae and femora of the mice, counted by CD31 staining. Mean values \pm SD for groups of 10 mice are shown. * $P > .05$; ** $P < .001$; *** $P < .05$; **** $P < .02$.

Nightingale TD, Pattni K, Hume AN, Seabra MC, Cutler DF. Rab27a and MyRIP regulate the amount and multimeric state of VWF released from endothelial cells. *Blood*. 2009;113(20):5010-5018.

On page 5010 in the 14 May 2009, issue, the institution "University College London, London, United Kingdom" of the first, second, and last authors (Nightingale, Pattni, and Cutler) was omitted from

the affiliations. The correct byline and affiliations should have read as shown. The error was corrected in the online version, which now differs from the print version.

Thomas D. Nightingale,¹ Krupa Pattni,¹ Alistair N. Hume,² Miguel C. Seabra,² Daniel F. Cutler¹

¹Medical Research Council Laboratory of Molecular Cell Biology, Cell Biology Unit and Department of Cell and Developmental Biology, University College London, London, United Kingdom; and ²National Heart and Lung Institute, Imperial College London, London, United Kingdom